An open label, parallel group, multicenter study, evaluating the safety and imaging characteristics of florbetapir (18F) in healthy volunteers, patients with mild cognitive impairment (MCI) and patients with Alzheimers disease (AD)
Phase 2
- Conditions
- Japanese Healthy Volunteers, MCI and AD
- Registration Number
- JPRN-jRCT2080221935
- Lead Sponsor
- Eli Lilly Japan K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 45
Inclusion Criteria
Japanese males or females at least 50 years of age.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method